Control Bionics (ASX:CBL) Asset Impairment Charge : A$0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Control Bionics Asset Impairment Charge?

Control Bionics's Asset Impairment Charge for the six months ended in Dec. 2024 was A$0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2024 was A$0.00 Mil.

Control Bionics Asset Impairment Charge Historical Data

The historical data trend for Control Bionics's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Control Bionics Asset Impairment Charge Chart

Control Bionics Annual Data

Trend

Jun21

Jun22

Jun23

Jun24

Asset Impairment Charge

Control Bionics Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Asset Impairment Charge	Get a 7-Day Free Trial				-	-	-	-	-

Control Bionics Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Control Bionics Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Control Bionics's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Control Bionics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Control Bionics Ltd (ASX:CBL) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

N/A

Address

11-13 Pearson Street, Level 4, Cremorne, VIC, AUS, 3121

Website

https://www.controlbionics.com

Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically it derives a majority of revenue from North America and has its presence in Australia as well.